Filing Flows › Comparisons › UPB vs IRD
Upstream Bio vs Opus Genetics: UPB and IRD compared
Upstream Bio is the larger company: $773K of revenue in its latest quarter (Q2 2026) against $755K for Opus Genetics (Q2 2026). Upstream Bio is growing faster (-18% against -74% a year earlier).
Where the money goes: UPB and IRD
Upstream Bio (UPB) · Q2 2026
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
Opus Genetics (IRD) · Q2 2026
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Upstream Bio (UPB) | Opus Genetics (IRD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $773K | $755K |
| Revenue growth, Y/Y | -18% | -74% |
| Operating margin | n/m | n/m |
| Net earnings | −$39.7M | −$8.1M |
| Operating cash flow | −$35.6M | −$11.9M |
Questions
Which is bigger, Upstream Bio or Opus Genetics?
Upstream Bio is the larger company: $773K of revenue in its latest quarter (Q2 2026) against $755K for Opus Genetics (Q2 2026).
Is Upstream Bio or Opus Genetics growing faster?
Upstream Bio is growing faster (-18% against -74% a year earlier).
More: Upstream Bio earnings · how Upstream Bio makes money · Opus Genetics earnings · how Opus Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.